Diagnosis and Risk Stratification
An algorithmic approach to guide diagnosis
Our updated approach to fluorescence in-situ hybridization (FISH) testing takes into account the fact that multiple myeloma is increasingly recognized as more than one disease, and is characterized by cytogenetic, molecular, and proliferative heterogeneity. While novel agents and combinations are rapidly redefining the treatment paradigm, patient outcomes vary based on risk stratification.
Created in conjunction with Mayo Clinic’s multiple myeloma clinical practice, mSMART uses flow cytometry, FISH, and the latest consensus to determine a patient’s genetic risk of developing multiple myeloma to better inform individualized treatment plans and provides clinicians with a comprehensive and correlated patient profile.
Which test should I order?
A Test in Focus
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in-situ hybridization (FISH) panels, rather than chromosome studies.
A comparison of testing approaches
Learn more about how to order these evaluations at your institution.
mSMART: Stratification for myeloma and risk-adapted therapy
The group's mission is to present the state-of -the-art approach to management of these plasma cells disorders including Myeloma, Amyloidosis, and Waldenstrom's Macroglobulinemia. Views expressed here are opinions of a group of experts, based on best available evidence.